Articles

Elephants or finches? The need for healthcare communications to develo…

24th April 2014

Elephants or finches? The need for healthcare communications to develop for the futureChris Stevenson

Chris Stevenson of Protinus Solutions explores the evolving needs of pharma clients and how the world of healthcare communications needs to keep adapting to meet clients' future needs.As someone who... Read more

Pharma products, patents & problems – the Unified Patent Court: pl…

24th April 2014

Pharma products, patents & problems – the Unified Patent Court: plan your patent strategyLaura Barrell and Paul Gershlick

As we see the patent system in Europe undergo its biggest overhaul in decades, we explore the new Unified Patent Court Agreement and how it will impact on your patent... Read more

A.N.A.L.Y.T.I.C.S corner - A Necessary Approach: Leveraging Your Targe…

23rd April 2014

A.N.A.L.Y.T.I.C.S corner - A Necessary Approach: Leveraging Your Target’s Insights Creatively & StrategicallyAdrian Smith

Adrian Smith of Havas Life Metro shares his thoughts on how to interpret and integrate successful mobile campaigns in pharmaceutical marketing.Build it and they will come –interpreting & integrating mobile... Read more

Understanding the natural history of disease – a fundamental strategy …

23rd April 2014

Understanding the natural history of disease – a fundamental strategy during drug development and beyondAnnette Stemhagen

How important is it to understand the natural history of disease before embarking on drug development? Annette Stemhagen of United BioSource Corporation discusses.Having an in-depth understanding of the disease or... Read more

News

Lilly’s profits cut in half in Q1

24th April 2014

Lilly’s profits cut in half in Q1Andrew McConaghie

Lilly saw its profits plummet 53% in the first three months of 2014, undermined by two major patent expiries. The US firm saw its worldwide sales fall 16% compared with... Read more

Europe contributes to Sovaldi, the overnight blockbuster

24th April 2014

Europe contributes to Sovaldi, the overnight blockbusterAndrew McConaghie

New Hepatitis C treatment Sovaldi has enjoyed an unprecedented success in its first three months on the market, producing sales of $2.1 billion for Gilead.The US pharma company confirmed the... Read more

Roche’s Kadcyla ‘unaffordable’ for NHS

23rd April 2014

Roche’s Kadcyla ‘unaffordable’ for NHSAndrew McConaghie

Roche's new breast cancer treatment Kadcyla has been rejected by NICE in draft guidance, with the cost effectiveness watchdog criticising the high price set by the company.NICE says Kadcyla costs... Read more

Sarepta and FDA agree plan for Muscular Dystrophy drug

22nd April 2014

Sarepta and FDA agree plan for Muscular Dystrophy drugAndrew McConaghie

Sarepta has overcome a major regulatory obstacle and now plans to file its Duchenne Muscular Dystrophy treatment with the FDA by the end of 2014. The US company had received a... Read more

Audio & Video

Rare Disease Day tweetchat

 

To view a full transcript of the discussion from this #hcsmeu tweetchat held on 28th February 2014 please click View more

Is there common ground for engagement be…

Doctors net webinar

 

The growth of online networks for doctors has been accompanied by recognition from the pharmaceutical industry that these digital meeting grounds can be... View more

Executive Perspectives: Jane Griffiths

 

In the latest in our series of interviews with senior executives who are steering the global pharma industry through a period of unparalleled change, pharmaphorum... View more

Full round table: Oncology shaping the …

 

Watch the full round table video debate on 'oncology shaping the... View more

White Papers

Who are the pharma social media butterfl…

Who are the pharma social media butterflies?Joanne Wunder, Caroline Howe, Andrea Visone and Laura Clewes

Social media has got everyone talking and it seems like everyone in pharma is talking about social media, so Ogilvy Healthworld figured it was time to analyse who were the... View info

Engage with confidence: Managing online …

Engage with confidence: Managing online adverse event reportingSiva Nadarajah

The pharmaceutical industry is waking up to the enormous potential offered by social media and other online data sources for informing better decisions around drug development and commercialization. Here, Siva... View info

Digital excellence in the global pharmac…

Digital excellence in the global pharmaceutical industry in 2014Tim van Tongeren and Dennis van Rooij

As pharmaceutical companies all look to step up their digital capabilities, this survey of digital leaders from across big pharma, exclusively first published on pharmaphorum, reveals an interesting picture of... View info

Patient research – the changing landscap…

Patient research – the changing landscape: Harnessing the voice of the citizen expertBrian Mondry and Jo Boxall

Empowered patients, or citizen experts as they are often called, are becoming one of the most powerful forces in healthcare, which means the pharmaceutical industry must learn to effectively engage... View info

Further News & Articles

The technological tipping point for pharma sales and marketing

In the wake of the eyeforpharma Barcelona event, IMS Health's Kabir Shahani and Barry Crowther present the case for ... Read more

Articles

Digital pharma update: loves me, loves me not?

In her latest article, Denise Silber, founder of Doctors 2.0 & You conference, a pharmaphorum partner, explores ... Read more

Articles

NHS England approves early funding for Sovaldi

NHS England is to spend £18.7 million to make new Hepatitis C treatment Sovaldi available to patients with th... Read more

News

Pharma Gets Social: Pinterest for Pharma, revisited

Daniel Ghinn provides an update on pharma's use of Pinterest since he last wrote about it two years ago. He updat... Read more

Articles

Tunnah’s musings: Social media in the pharma boardroom

Attending the Boehringer Ingelheim annual press conference, Paul Tunnah took the opportunity to catch up with its he... Read more

Articles

US approval for Glaxo’s Tanzeum

GlaxoSmithKline has gained FDA approval for its new diabetes treatment Tanzeum.

The drug ... Read more

News